Sanofi - Aventis Groupe: Press Release: FDA accepts nirsevim

FDA accepts nirsevimab application as first protective option against RSV disease for all infants Nirsevimab would be the first broadly protective option against RSV disease designed for all infants

Related Keywords

White House , District Of Columbia , United States , Illinois , United Kingdom , Japan , Paris , France General , France , Langley , Northumberland , China , Chicago , American , Eva Schaefer Jansen , William Muller , Evan Berland , Corentine Driancourt , Felix Lauscher , Kate Conway , Ann Roberth Lurie , Thomas Triomphe , Nathalie Pham , Sandrine Guendoul , Sally Bain , Priya Nanduri , American Academy Of Pediatrics , Nasdaq , Northwestern University Feinberg School Of Medicine , Astrazeneca , Japan Agency For Medical Research , China Center , Centers For Disease , Drug Administration , European Commission , Community Trials , Regulatory Agency , National Medical Products Administration , European Medicines Agency Ema Priority , Euronext , Drug Evaluation , Biologics License Application , Prescription Drug User Fee Act , Vice President , Disease Control , United Stated , American Academy , Northwestern University Feinberg School , Scientific Director , Breakthrough Therapy Designation , Breakthrough Therapy Designati , European Medicines Agency , Promising Innovative Medicine , United Kingdom Medicines , Drug Selection , Promote New Drug Development , Japan Agency , Medical Research , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Healthy Late Preterm , Medically Attended , Term Infants , Accessed December , Healthy Preterm , Single Dose Nirsevimab , Lung Disease , Medically Attended Respiratory Syncytial Virus , Lower Respiratory Track Infection , Product Characteristics , Attended Illness , United States Between , Englj Medicine , Sanofi , Eventis , Roupe , Dress , Release , Oaccepts , Nirsevimab , Application , First , Protective , Option , Against , Disease , Infants ,